These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 39375657)

  • 1. Efficacy and safety of Anlotinib based neoadjuvant chemotherapy for locally advanced triple negative breast cancer (TNBC).
    Ren K; Wang S; Ye T; Zhu Z; Hong S; Wang S; Liu J
    BMC Cancer; 2024 Oct; 24(1):1237. PubMed ID: 39375657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Efficiency and Toxicity Of Anlotinib in Combination With Docetaxel Followed by Epirubicin and Cyclophosphamide Regimen as Neoadjuvant Treatment in IIB to IIIA Triple Negative Breast Cancer: A Single-Arm, Multicenter, Open-Label, Phase II Study.
    Chen X; Wei X; Yao P; Liu Y; Guan H; Kang H; Liu D; Diao Y; Ma X; Min W; Shan C; Zhao Y; Zhao F; Chen Y; Xiao D; She Q; Liu Y; Zhang Y; Zhang S
    Clin Breast Cancer; 2024 Jun; 24(4):e195-e202. PubMed ID: 38670862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of anlotinib combined with taxane and lobaplatin in neoadjuvant treatment of clinical stage II/III triple-negative breast cancer in China (the neoALTAL trial): a single-arm, phase 2 trial.
    Liang Y; Liu J; Ge J; Shi Q; Zhang G; Wan A; Luo T; Tian H; Fan L; Wang S; Chen L; Tang P; Zhu K; Jiang J; Bian X; Zhang Y; Qi X
    EClinicalMedicine; 2024 May; 71():102585. PubMed ID: 38638401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of intra-arterial neoadjuvant chemotherapy through the superior epigastric artery in the treatment of locally advanced triple negative breast cancer.
    Jin HY; He W; Liu Q; Wang XF; Liu YF; Wei ZX
    Neoplasma; 2016; 63(4):607-16. PubMed ID: 27268925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial.
    Schneeweiss A; Möbus V; Tesch H; Hanusch C; Denkert C; Lübbe K; Huober J; Klare P; Kümmel S; Untch M; Kast K; Jackisch C; Thomalla J; Ingold-Heppner B; Blohmer JU; Rezai M; Frank M; Engels K; Rhiem K; Fasching PA; Nekljudova V; von Minckwitz G; Loibl S
    Eur J Cancer; 2019 Jan; 106():181-192. PubMed ID: 30528802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial.
    Li J; Yu K; Pang D; Wang C; Jiang J; Yang S; Liu Y; Fu P; Sheng Y; Zhang G; Cao Y; He Q; Cui S; Wang X; Ren G; Li X; Yu S; Liu P; Qu X; Tang J; Wang O; Fan Z; Jiang G; Zhang J; Wang J; Zhang H; Wang S; Zhang J; Jin F; Rao N; Ma B; He P; Xu B; Zhuang Z; Wang J; Sun Q; Guo X; Mo M; Shao Z;
    J Clin Oncol; 2020 Jun; 38(16):1774-1784. PubMed ID: 32275467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label phase II trial.
    Zhang L; Wu ZY; Li J; Lin Y; Liu Z; Cao Y; Zhang G; Gao HF; Yang M; Yang CQ; Zhu T; Cheng MY; Ji F; Li J; Wang K
    Int J Cancer; 2022 Feb; 150(4):654-662. PubMed ID: 34591977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety.
    Shimada H; Ueda S; Saeki T; Shigekawa T; Takeuchi H; Hirokawa E; Sugitani I; Sugiyama M; Takahashi T; Matsuura K; Yamane T; Kuji I; Hasebe T; Osaki A
    Jpn J Clin Oncol; 2015 Jul; 45(7):642-9. PubMed ID: 25989989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unfavorable pathological complete response rate of neoadjuvant chemotherapy epirubicin plus taxanes for locally advanced triple-negative breast cancer.
    Yin Y; Zhang P; Xu BH; Zhang BL; Li Q; Yuan P; Cai RG; Wang JY; Wang X; Xu XZ
    J Huazhong Univ Sci Technolog Med Sci; 2013 Apr; 33(2):262-265. PubMed ID: 23592141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: improved prognosis in triple-negative tumors.
    Medioni J; Huchon C; Le Frere-Belda MA; Hofmann H; Bats AS; Eme D; Andrieu JM; Oudard S; Lecuru F; Levy E
    Drugs R D; 2011; 11(2):147-57. PubMed ID: 21679005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem).
    McCarthy N; Boyle F; Zdenkowski N; Bull J; Leong E; Simpson A; Kannourakis G; Francis PA; Chirgwin J; Abdi E; Gebski V; Veillard AS; Zannino D; Wilcken N; Reaby L; Lindsay DF; Badger HD; Forbes JF;
    Breast; 2014 Apr; 23(2):142-51. PubMed ID: 24393617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superior outcome after neoadjuvant chemotherapy with docetaxel, anthracycline, and cyclophosphamide versus docetaxel plus cyclophosphamide: results from the NATT trial in triple negative or HER2 positive breast cancer.
    Chen X; Ye G; Zhang C; Li X; Chen Y; Xie X; Zheng H; Cao Y; Wu K; Ni D; Tang J; Wei Z; Shen K
    Breast Cancer Res Treat; 2013 Dec; 142(3):549-58. PubMed ID: 24292815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase II Trial.
    Yang H; Xu L; Guan S; Hao X; Ge Z; Tong F; Cao Y; Liu P; Zhou B; Cheng L; Liu M; Liu H; Xie F; Wang S; Peng Y; Wang C; Wang S
    BMC Cancer; 2022 Dec; 22(1):1357. PubMed ID: 36577958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Efficacy and Safety of Anlotinib in Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Single-Arm Phase II Clinical Trial.
    Huang NS; Wei WJ; Xiang J; Chen JY; Guan Q; Lu ZW; Ma B; Sun GH; Wang YL; Ji QH; Wang Y
    Thyroid; 2021 Dec; 31(12):1808-1813. PubMed ID: 34610756
    [No Abstract]   [Full Text] [Related]  

  • 15. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
    Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
    Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nab-paclitaxel Followed by Dose-dense Epirubicin/Cyclophosphamide in Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Phase II Study.
    Liu Y; Fan L; Wang ZH; Shao ZM
    Oncologist; 2023 Jan; 28(1):86-e76. PubMed ID: 36426808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Randomized Parallel Controlled Phase II Trial of Recombinant Human Endostatin Added to Neoadjuvant Chemotherapy for Stage III Breast Cancer.
    Zhang X; Zhang Z; Cao M; Liu B; Mori M; Luoh SW; Bergan R; Liu Y; Liu Y
    Clin Breast Cancer; 2020 Aug; 20(4):291-299.e3. PubMed ID: 32482525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathological response and clinical outcomes in operable triple-negative breast cancer with cisplatin added to standard neoadjuvant chemotherapy.
    Georgy JT; Singh A; John AO; Joel A; Andrews AG; Thumaty DB; Rebekah G; Sigamani E; Chandramohan J; Manipadam MT; Cherian AJ; Abraham DT; Paul MJ; Balakrishnan R; Backianathan S; Chacko RT
    Klin Onkol; 2021; 34(1):49-55. PubMed ID: 33657819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Dose-Escalating Pilot Study (NCT03017404) of Pegylated Liposomal Doxorubicin and Cyclophosphamide, Followed by Docetaxel Administration as a Neoadjuvant Chemotherapy Regimen in Patients with Locally Advanced Breast Cancer.
    Cheng M; Song Z; Qi Y; Wang X; Zhang L; Shi J; Wang M
    Oncol Res Treat; 2019; 42(5):269-274. PubMed ID: 30943501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial.
    Zhang P; Yin Y; Mo H; Zhang B; Wang X; Li Q; Yuan P; Wang J; Zheng S; Cai R; Ma F; Fan Y; Xu B
    Oncotarget; 2016 Sep; 7(37):60647-60656. PubMed ID: 27447966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.